219 related articles for article (PubMed ID: 26888723)
1. Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
Evans DG; Lalloo F; Howell S; Verhoef S; Woodward ER; Howell A
Breast Cancer Res Treat; 2016 Feb; 155(3):597-601. PubMed ID: 26888723
[TBL] [Abstract][Full Text] [Related]
2. Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.
Evans DG; Woodward ER; Howell SJ; Verhoef S; Howell A; Lalloo F
Fam Cancer; 2017 Apr; 16(2):173-179. PubMed ID: 27796713
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Muendlein A; Rohde BH; Gasser K; Haid A; Rauch S; Kinz E; Drexel H; Hofmann W; Schindler V; Kapoor R; Decker T; Lang AH
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2005-12. PubMed ID: 25971625
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
Guzmán-Arocho YD; Rosenberg SM; Garber JE; Vardeh H; Poorvu PD; Ruddy KJ; Kirkner G; Snow C; Tamimi RM; Peppercorn J; Schapira L; Borges VF; Come SE; Brachtel EF; Marotti JD; Warner E; Partridge AH; Collins LC
Br J Cancer; 2022 Feb; 126(2):302-309. PubMed ID: 34703009
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
Villarreal-Garza C; Weitzel JN; Llacuachaqui M; Sifuentes E; Magallanes-Hoyos MC; Gallardo L; Alvarez-Gómez RM; Herzog J; Castillo D; Royer R; Akbari M; Lara-Medina F; Herrera LA; Mohar A; Narod SA
Breast Cancer Res Treat; 2015 Apr; 150(2):389-94. PubMed ID: 25716084
[TBL] [Abstract][Full Text] [Related]
7. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
8. Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.
McCrorie AD; Ashfield S; Begley A; Mcilmunn C; Morrison PJ; Boyd C; Eccles B; Greville-Heygate S; Copson ER; Cutress RI; Eccles DM; Savage KI; McIntosh SA
J Pathol Clin Res; 2020 Apr; 6(2):146-153. PubMed ID: 32022473
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
10. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
13. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
Akkoc Mustafayev FN; Shukla MA; Lanier A; Milton DR; Gutierrez AM; Gruschkus SK; Lewis JE; Murthy RK; Arun BK
Cancer; 2024 May; 130(9):1600-1608. PubMed ID: 38100492
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
[TBL] [Abstract][Full Text] [Related]
17. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
[TBL] [Abstract][Full Text] [Related]
18. Real-world multi-country study of
Lux MP; Lewis K; Rider A; Niyazov A
Future Oncol; 2022 Mar; 18(9):1089-1101. PubMed ID: 35098723
[TBL] [Abstract][Full Text] [Related]
19. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
Wang X; Liu H; Maimaitiaili A; Zhao G; Li S; Lv Z; Wu D; Shi A; Guan X; Jia H; Li M; Song D; Kang L; Han B; Fu T; Yang M; Zhu Z; Du Y; Song Y; Hong J; Fan Z
Mol Genet Genomic Med; 2019 Jun; 7(6):e677. PubMed ID: 30968603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
